Friday , August 17 2018
Home / Letter From The Editor / Letter from the Editor #485

Letter from the Editor #485

Sep 9, 2009

There are two things that we have spent time bringing you information on over the past few weeks that won’t seem to go away.  

The GDH-PQQ monitoring controversy has moved to the hospital setting as companies using different enzymes see a way to get their product on formulary. At least in the hospital setting there is reason to be concerned. 

Eli Lilly and Company has been working with the ISMP to develop safer protocols for the use of U-500 insulin. To help avoid potential problems they mailed dosing information letters to medical professionals. The information contained in their mailing leans towards the use of the term “unit markings” rather than units, and it makes sense that we should start using that nomenclature in practice. Look for more information in the near future.  

Strokes are increasing in our diabetes patients as they age and tPA has been the standard of care in the emergency room, but within 3 hours or forget it. Now in a new consensus from the American Heart Association (AHA)/American Stroke Association (ASA) the use of tissue plasminogen activator (tPA) to treat acute ischemic stroke can be used up to 4.5 hours after symptom onset. Ralph L. Sacco, MD, President Elect AHA, offers his thoughts on this new time window.

Now that the weather is cooling and the kids are back in school, many of our patients want to crank up their physical activity. Sheri Colberg, Ph.D., FACSM, has been talking about Injuries Related to Being Active with Diabetes, and this week she brings us Part 2 (Prevention of Overuse Injuries).


New Horizons in the Management of Type 2 Diabetes: Optimizing Glycemic Control and Risk Reduction.

Although treatment options for the management of diabetes have improved over the past decade, maintaining glycemic control remains a challenge. Inadequate glycemic control may be attributable to the progressive nature of the disease, a delay in initiating pharmacotherapy, and a failure to intensify treatment when appropriate.

Advances in the understanding of the mechanisms involved in glycemic control as well as the derangements of those processes in patients with Type 2 diabetes have led to the identification of novel treatment approaches. This CME is designed to give clinicians knowledge to more aggressively manage patients.


dLife: September 13, 7PM ET on CNBC

NEW! Diabetes is the leading cause of non-traumatic lower limb amputation. Get the information you need to help your patients avoid becoming statistics. Also, the latest advances in the artificial pancreas; your exercise questions answered by dLife’s doctor on call; and a pro athlete whose face-off with diabetes happens on and off the ice. Make the most of your dLife and don’t miss an episode: Sundays on CNBC at 7 PM ET, 6 PM CT, and 4 PM PT.


TCOYD Diabetes Conference, September 19,2009
Join the “Taking Control of Your Diabetes” staff and enjoy a whole day of learning about your diabetes. TCOYD will be in Milwaukee, Wisconsin on Sept. 19th. Just go to and register. 



We can make a difference!



Check out this week’s “Test Your Diabetes Knowledge” question.

Dave Joffe, Editor-in-chief